These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7499447)

  • 61. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
    Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
    Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma.
    Thiounn N; Mathiot C; Dorval T; Flam TA; Tartour E; Mosseri V; Zerbib M; Fridman WH; Debre B
    Br J Urol; 1995 May; 75(5):586-9. PubMed ID: 7613793
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
    Keilholz U; Conradt C; Legha SS; Khayat D; Scheibenbogen C; Thatcher N; Goey SH; Gore M; Dorval T; Hancock B; Punt CJ; Dummer R; Avril MF; Bröcker EB; Benhammouda A; Eggermont AM; Pritsch M
    J Clin Oncol; 1998 Sep; 16(9):2921-9. PubMed ID: 9738559
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
    Ellerhorst JA; Sella A; Amato RJ; Tu SM; Millikan RE; Finn LD; Banks M; Logothetis CJ
    Cancer; 1997 Dec; 80(11):2128-32. PubMed ID: 9392335
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 67. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.
    Vuoristo M; Jantunen I; Pyrhönen S; Muhonen T; Kellokumpu-Lehtinen P
    Eur J Cancer; 1994; 30A(4):530-2. PubMed ID: 8018415
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
    Boorjian S
    Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 71. A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
    Zustovich F; Cartei G; Dal Bianco M; De Zorzi L; Ceravolo R; Zovato S; Salmaso F; Binato S; Artioli G; Cingarlini S; Pastorelli D
    Ann Oncol; 2006 May; 17 Suppl 5():v133-6. PubMed ID: 16807442
    [No Abstract]   [Full Text] [Related]  

  • 72. Systemic therapy for renal cell carcinoma.
    Ko YJ; Atkins MB
    Cancer Chemother Biol Response Modif; 2005; 22():263-72. PubMed ID: 16110616
    [No Abstract]   [Full Text] [Related]  

  • 73. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
    Padrik P
    Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Novel concepts in the staging of renal cell carcinoma.
    Leibovici D; Lindner A; Sella A; Zisman A
    Curr Urol Rep; 2003 Feb; 4(1):41-8. PubMed ID: 12537938
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic factors for biologic therapy in kidney cancer.
    Drucker BJ
    Curr Urol Rep; 2002 Feb; 3(1):31-6. PubMed ID: 12084217
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.
    Canobbio L; Rubagotti A; Miglietta L; Cannata D; Curotto A; Amoroso D; Boccardo F
    J Cancer Res Clin Oncol; 1995; 121(12):753-6. PubMed ID: 7499447
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.
    Fosså SD; Kramar A; Droz JP
    Eur J Cancer; 1994; 30A(9):1310-4. PubMed ID: 7999419
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.